# Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors

> **NCT06823609** · PHASE1 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** QLS1304 tablet

## Key facts

- **NCT ID:** NCT06823609
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-06
- **Primary completion:** 2026-11
- **Final completion:** 2027-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06823609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06823609, "Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06823609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*